ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 2225 • 2013 ACR/ARHP Annual Meeting

    COVA322: A Novel, Bispecific Tumor-Necrosis-Factor-Alpha / Interleukin-17A (TNF/IL-17A) Inhibitor With Excellent Pharmacokinetic Properties In Mice and Cynomolgus Monkeys

    Mathias Locher, Dragan Grabulovski, Isabella Attinger-Toller, Susann Koenig-Friedrich, Ulrike von der Bey and Julian Bertschinger, Covagen AG, Schlieren, Switzerland

    Background/Purpose: The generation of bispecific antibody molecules with excellent biophysical and pharmacokinetic properties has been a challenging task in the past. We present here COVA322,…
  • Abstract Number: 410 • 2013 ACR/ARHP Annual Meeting

    Correlation of  Carotid Intima Media Thickness With Interleukin-6, Tumor Necrosis Factor-α and Anti-Cyclic Citrullinated Peptides In Rheumatoid Arthritis

    Lourdes Nuñez Atahualpa1, Mauricio Figuroa Sanchez1, Daniel Alberto Rocha Muñoz2, Raul Vargas Ramirez3, Beatriz Teresita Martin Marquez4, Jorge Ivan Gamez Nava5, Laura González López6, Erika Martínez García3, Esther Sanchez Corona3, Marcelo Petri4, Rosa Navarro Hernandez3, Veronica Gonzalez Diaz7, Jorge Aguilar Arreola8, Ana Guisllaine Bernard Medina9, Alejandra Nuñez Atahualpa10, Javier Andrade Garduño10, Eduardo Gomez Bañuelos3 and Monica Vazquez Del Mercado4,8, 1Radiology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, 2Unidad de Investigación en Epidemiología Clínica del Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, 3CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, 4Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, 5Unidad de Investigación en Epidemiología Clínica, Hospital de Especialidades Centro Médico Nacional de Occidente., Guadalajara, Jalisco, Mexico, 6Medicina Interna-Reumatología, Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social., Guadalajara, Jalisco, Mexico, 7Reumatologia, Antiguo Hospital Civil de Guadalajara - Fray Antonio Alcalde, Guadalajara, Mexico, 8Rheumatology, Hospital Civil Dr Juan I Menchaca, Guadalajara, Mexico, 9Rheumatology, Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, 10Universidad Autónoma de Guadalajara, Guadalajara, Mexico

    Background/Purpose: The main cause of death in rheumatoid arthritis patients are cardiovascular events which cannot be entirely explained by traditional risk factors, suggesting, that systemic…
  • Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting

    Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties

    Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Biology, Metabolex, Inc., Hayward, CA

    Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…
  • Abstract Number: 600 • 2012 ACR/ARHP Annual Meeting

    Regulatory T Cells in Spondyloarthritis (SpA) Animal Model and Modulatory Role of Inducible Costimulator (ICOS)

    Luiza Krause1, Ingrid Fert1, Karine Labroquère2, Muriel Andrieu2, Gilles Chiocchia3 and Maxime A. Breban4, 1Immunology and Hematology Department, Institut Cochin - INSERM U1016 - CNRS (UMR 8104)-Université Paris Descartes (UMR-S 1016), Paris, France, 2Cochin Immunobiology Facility, Paris, France, 3Versailles Saint Quentin en Yvelines University, INSERM U987, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France, 4Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France

    Background/Purpose: HLA-B27/human β2m transgenic rats (B27-rats), a model of SpA develop spontaneous colitis and arthritis. It was recently shown in this model that IL-17 producing…
  • Abstract Number: 1492 • 2012 ACR/ARHP Annual Meeting

    IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis

    Yuko Ota1, Yasushi Kawaguchi1, Atsushi Kitani2, Kae Takagi1, Hisae Ichida1, Yasuhiro Katsumata1, Takahisa Gono1, Masanori Hanaoka1, Yuko Okamoto1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Mucosal Immunity Section, NIAID/NIH, Bethesda, MD

    Background/Purpose: Interleukin (IL)-13 is a pleiotropic cytokine involved in T helper type 2 cell immune response and in the development of fibrotic conditions such as…
  • Abstract Number: 434 • 2012 ACR/ARHP Annual Meeting

    IL-22 Mediated Pannus Formation in Autoimmune Arthritis Is PI3K/Akt/mTOR Dependent

    Siba P. Raychaudhuri1, Anupam Mitra1, Ananya Datta Mitra2, Christine Abria2 and Smriti K. Raychaudhuri2, 1Rheumatology, VA Sacramento Medical CenterUC Davis School of Medicine, Mather, CA, 2Rheumatology, VA Sacramento Medical Center, Mather, CA

    Background/Purpose: IL-22, a Th17 cytokine plays a key role in the formation of “pannus” in autoimmune arthritis such as rheumatoid arthritis (RA) and psoriatic arthritis…
  • Abstract Number: 1337 • 2012 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis

    Pavel Belomestnov1, Jennifer Hamilton2, A. Thomas DiCioccio1, Martine Jasson3 and Allen R. Radin4, 1Pharmacometrics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3Clinical Development, Sanofi-Aventis, Paris, France, 4Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY

    Background/Purpose: Sarilumab, a fully human monoclonal antibody targeting interleukin-6 receptor alpha (IL-6Rα), is being evaluated for the treatment of rheumatoid arthritis (RA) based on the…
  • Abstract Number: 429 • 2012 ACR/ARHP Annual Meeting

    The Significance of the Apoptosis Level and the Apoptosis Related Signal Proteins of CD4+t�ACD4+Foxp3+t Cell in Patients with Rheumatoid Arthritis

    Ning Li1, Tianrui Ma2, Jie Han1, Jieru Zhou1 and Songguo Zheng3, 1Rheumatology, Shanghai East Hospital, Shanghai, China, 2Rheumatology, Ningbo Pediatric Hospital, Ningbo, China, 3Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA

    Background/Purpose: To investigate the apoptosis of CD4+T cell and Tregs in the pathogenesis and disease activity of rheumatoid arthritis patients. Methods: Isolated lymphocytes from human…
  • Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting

    Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis

    Mark C. Genovese1, Roy Fleischmann2, Martine Jasson3, Allen R. Radin4, Jennifer Hamilton5 and Tom W.J. Huizinga6, 1Division of Rheumatology, Stanford University, Palo Alto, CA, 2Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, 3Clinical Development, Sanofi-Aventis, Paris, France, 4Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…
  • Abstract Number: 332 • 2012 ACR/ARHP Annual Meeting

    Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-17 Differentiation

    Kazuhisa Nozawa1, Maki Fujishiro2, Ayako Yamaguchi1, Mikiko Kawasaki2, Shouzou Ichinose2, Mitsuaki Yanagida2, Kazuhisa Iwabuchi2, Keigo Ikeda3, Shinji Morimoto4, Megumi Morioka5, Yoshinari Takasaki6 and Iwao Sekigawa3, 1Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, 3Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, 4Juntendo University Urayasu Hospital, Tokyo, Japan, 5Nihon Nosan Corporation, Nihon Nosan Corporation, Kanagawa, Japan, 6Internal Medicine and Rheumatology,, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Our previous study demonstrated changes in the profiles of serum protein biomarkers in infliximab-treated rheumatoid arthritis (RA) patients using a novel approach to proteomic…
  • Abstract Number: 1329 • 2012 ACR/ARHP Annual Meeting

    Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover

    Anne C. Bay-Jensen1, Inger Byrjalsen2, Andrew Kenwright3, Thierry Sornasse4, Claus Christiansen5 and Morten Asser Karsdal6, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Research & Development, Nordic Bioscience, Herlev, Denmark, 3Roche, Welwyn Garden City, United Kingdom, 4Genentech, South San Francisco, 5CCBR, Ballerup, Denmark, 6Nordic Bioscience A/S, Herlev, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by poly-articular inflammation, cartilage loss, synovial inflammation, subchondral bone erosion, and joint space narrowing. In…
  • Abstract Number: 336 • 2012 ACR/ARHP Annual Meeting

    Preclinical Development of ALX-0061, an Anti-IL-6R Nanobody® For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile

    Maarten Van Roy1, Hans Ulrichts2, Stefaan Rossenu2, Sandy Jacobs2, Sofie Poelmans3, Gert Verheyden2, Michel Vierboom4, Bert 't Hart4, Judith Baumeister1 and Josefin-Beate Holz5, 1Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 2Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 3Pharmacology, Ablynx NV, Gent, Belgium, 4Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, 5Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor IL-6R. IL-6 plays an important role in the…
  • Abstract Number: 2502 • 2012 ACR/ARHP Annual Meeting

    Neutrophil Extracellular Trap-Associated Protein Activation of the Inflammasome Is Enhanced in Lupus M1 Macrophages

    J. Michelle Kahlenberg1, Carolyne K. Smith2, Carmelo Carmona-Rivera1 and Mariana J. Kaplan3, 1Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD

    Background/Purpose: Neutrophil extracellular traps (NETs) contain numerous bactericidal proteins and are an important defense mechanism against microorganisms.  Clearance of NETs is impaired in a subset…
  • Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting

    Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment

    Steven De Bruyn1, Béla Gachályi2, Bernadette Rojkovich3, Slavomir Bruk4, Petr Sramek5, Mariusz Korkosz6, Krzysztof Krause7, Pieter Schoen8, Laura Sargentini-Maier9, Joke D'Artois10, Katrien Verschueren10, Katelijne De Swert10, Gerhard Arold11 and Josefin-Beate Holz12, 1Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, 2Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Péterfy Sándor Utcai Kórház, Budapest, Hungary, 3II. sz. Reumatológiai Osztály, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, 4Interni oddeleni, Nemocnice Trinec, Trinec, Czech Republic, 5Pharmaceutical Research Associates CZ, Praha, Czech Republic, 6Malopolskie Centrum Medyczne, Krakow, Poland, 7Specjalistyczny im. J. Gromkowskiego, Wojewodzki Szpital, Wroclaw, Poland, 8Project Management, Ablynx N.V., Zwijnaarde, Belgium, 9Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, 10Clinical Development, Ablynx nv, Zwijnaarde, Belgium, 11Medical Affairs, PRA International GmbH, Berlin, Germany, 12Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium

    Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…
  • Abstract Number: 310 • 2012 ACR/ARHP Annual Meeting

    STAT3 Plays a Central Role in NLRP3 Inflammasome-Mediated IL-1β Production and Pyronecrosis

    Jehad H. Edwan1, Tri M. Tran2, Mones Abu-Asab3, Raphaela T. Goldbach-Mansky4 and Robert A. Colbert1, 1NIAMS NIH, Bethesda, MD, 2NIAMS/NIH, Bethesda, MD, 3NEI NIH, Bethesda, MD, 4Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

    Background/Purpose: Gain of function mutations in NLRP3 cause cryopyrin-associated periodic fever syndromes (CAPS), the most severe form of which is neonatal-onset multisystem inflammatory disease (NOMID),…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology